StockSelector.com
  Research, Select, & Monitor Monday, December 17, 2018 11:54:20 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Johnson & Johnson$129.82($3.18)(2.39%)

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Johnson & Johnson Reports 2017 Third-Quarter Results:
   Tuesday, October 17, 2017 6:40:00 AM ET

Johnson & Johnson (JNJ ) today announced sales of $19.7 billion for the third quarter of 2017, an increase of 10.3% as compared to the third quarter of 2016. Operational sales results increased 9.5% and the positive impact of currency was 0.8%. Domestic sales increased 9.7%. International sales increased 10.9%, reflecting operational growth of 9.3% and a positive currency impact of 1.6%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide, domestic and international sales each increased 3.8%.*

Net earnings and diluted earnings per share for the third quarter of 2017 were $3.8 billion and $1.37, respectively. Third-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion and a charge for after-tax special items of approximately $0.5 billion. Third-quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.2 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $5.2 billion and adjusted diluted earnings per share were $1.90, representing increases of 11.2% and 13.1%, respectively, as compared to the same period in 2016.* On an operational basis, adjusted diluted earnings per share also increased 10.1%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our Pharmaceutical business, and augmented by Actelion and other recent acquisitions across the enterprise that will continue to fuel growth," said Alex Gorsky, Chairman and Chief Executive Officer. "Our dedicated colleagues continue to focus on advancing our pipelines to bring innovative solutions to patients and consumers around the globe."

The Company increased its sales guidance for the full-year 2017 to a range of $76.1 billion to $76.5 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2017 to $7.25 - $7.30 per share.*

Worldwide Consumer sales of $3.4 billion for the third quarter 2017 represented an increase of 2.9% versus the prior year, consisting of an operational increase of 1.6% and a positive impact from currency of 1.3%. Domestic sales decreased 0.5%, international sales increased 5.1%, which reflected an operational increase of 3.0% and a positive currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.1%, domestic sales decreased 0.7% and international sales increased 2.3%*.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products primarily TYLENOL? analgesic products and international smoking cessation aids; as well as OGX? and NEUTROGENA? beauty products partially offset by the negative impact of domestic baby care products.

During the quarter, the divestiture of COMPEED? to HRA Pharma was completed.

Worldwide Pharmaceutical sales of $9.7 billion for the third quarter 2017 represented an increase of 15.4% versus the prior year with an operational increase of 14.6% and a positive impact from currency of 0.8%. Domestic sales increased 15.4%; international sales increased 15.5%, which reflected an operational increase of 13.5% and a positive currency impact of 2.0%. Sales included the impact of the first full quarter of the acquisition of Actelion Ltd. which contributed 7.9%, to worldwide operational sales growth. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.7%, domestic sales increased 7.7% and international sales increased 5.1%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by new products and the strength of core products. Strong growth in new products include DARZALEX? (daratumumab), for the treatment of patients with multiple myeloma and IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA? (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, XARELTO? (rivaroxaban), an oral anticoagulant, ZYTIGA? (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer and INVEGA? SUSTENNA?/XEPLION?/TRINZA? (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

During the quarter, the U.S. Food and Drug Administration (FDA) approved an additional indication for IMBRUVICA? (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease after failure of one or more lines of systemic therapy. The European Commission granted approval for SYMTUZA? (darunavir/cobicistat/ emtricitabine/tenofovir alafenamide) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients aged 12 years and older.

New Drug Applications were submitted to the FDA for apalutamide, an oral androgen receptor inhibitor for men with non-metastatic castration-resistant prostate cancer and also for darunavir/cobicistat/emtricitabine/tenofovir alafenamide for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older. In addition, a supplemental New Drug Application (sNDA) was submitted to the FDA to expand the indication for ZYTIGA? (abiraterone acetate), in combination with prednisone and ADT to include treatment of patients with high-risk metastatic hormone na?ve prostate cancer or newly diagnosed, high-risk metastatic hormone sensitive prostate cancer.

The Company has made a decision not to pursue global approvals of sirukumab for the treatment of moderately to severely active rheumatoid arthritis. In addition, the clinical trial for talacotuzumab, an investigational compound being studied in patients with acute myeloid leukemia, has been discontinued.

Worldwide Medical Devices sales of $6.6 billion for the third quarter 2017 represented an increase of 7.1% versus the prior year consisting of an operational increase of 6.6% and a positive currency impact of 0.5%. Domestic sales increased 4.6%; international sales increased 9.6%, which reflected an operational increase of 8.6% and a positive currency impact of 1.0%. Sales included the impact of the acquisition of Abbott Medical Optics which contributed 5.2%, to worldwide operational sales growth. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.2%, domestic sales decreased 0.8% and international sales increased 3.2%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business, ACUVUE? contact lenses in the Vision Care business, and wound closure products in the General Surgery business, partially offset by declines in the Diabetes Care business.

During the quarter, the acquisitions of TearScience, Inc., a manufacturer of products dedicated to treating meibomian gland dysfunction and Sightbox, Inc., an e-commerce company that provides subscription vision care services connecting consumers with eye care professionals for their contact lens needs, were completed.

Subsequent to the quarter, the Company announced the completion of the divestiture of its Codman Neurosurgery business to Integra LifeSciences Holding Corporation.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 134,100 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company’s website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic and financial market factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures, including the Company’s ability to successfully integrate Actelion Ltd.’s products and operations and realize the expected benefits and opportunities of the transaction in the expected time frame or at all; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including in the section captioned "Cautionary Note Regarding Forward-Looking Statements," and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   THIRD QUARTER                                        NINE MONTHS
                                                         Percent Change                                       Percent Change
                                   2017       2016       Total    Operations  Currency  2017       2016       Total    Operations  Currency
Sales to customers by
segment of business
Consumer
U.S.                               $   1,285  $   1,291  (0.5) %  (0.5)       -         $   4,186  $   4,033  3.8   %  3.8         -
International                      2,071      1,970      5.1      3.0         2.1       5,876      5,842      0.6      0.2         0.4
                                   3,356      3,261      2.9      1.6         1.3       10,062     9,875      1.9      1.6         0.3
Pharmaceutical
U.S.                               5,816      5,042      15.4     15.4        -         15,698     15,123     3.8      3.8         -
International                      3,879      3,358      15.5     13.5        2.0       10,877     10,109     7.6      8.4         (0.8)
                                   9,695      8,400      15.4     14.6        0.8       26,575     25,232     5.3      5.6         (0.3)
Medical Devices
U.S.                               3,189      3,048      4.6      4.6         -         9,510      9,118      4.3      4.3         -
International                      3,410      3,111      9.6      8.6         1.0       10,108     9,559      5.7      6.3         (0.6)
                                   6,599      6,159      7.1      6.6         0.5       19,618     18,677     5.0      5.3         (0.3)
U.S.                               10,290     9,381      9.7      9.7         -         29,394     28,274     4.0      4.0         -
International                      9,360      8,439      10.9     9.3         1.6       26,861     25,510     5.3      5.8         (0.5)
Worldwide                          $ 19,650   $ 17,820   10.3  %  9.5         0.8       $ 56,255   $ 53,784   4.6   %  4.8         (0.2)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   THIRD QUARTER                                       NINE MONTHS
                                                        Percent Change                                     Percent Change
                                   2017      2016       Total    Operations  Currency  2017      2016      Total    Operations  Currency
Sales to customers by
geographic area
U.S.                               $ 10,290  $   9,381  9.7   %  9.7         -         $ 29,394  $ 28,274  4.0   %  4.0         -
Europe                             4,308     3,832      12.4     7.9         4.5       12,398    11,769    5.3      6.2         (0.9)
Western Hemisphere excluding U.S.  1,569     1,396      12.4     10.1        2.3       4,522     4,269     5.9      3.1         2.8
Asia-Pacific, Africa               3,483     3,211      8.5      10.6        (2.1)     9,941     9,472     5.0      6.4         (1.4)
International                      9,360     8,439      10.9     9.3         1.6       26,861    25,510    5.3      5.8         (0.5)
Worldwide                          $ 19,650  $ 17,820   10.3  %  9.5         0.8       $ 56,255  $ 53,784  4.6   %  4.8         (0.2)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 THIRD QUARTER
                                                                  2017                      2016                      Percent
                                                                                  Percent                   Percent   Increase
                                                                  Amount          to Sales  Amount          to Sales  (Decrease)
Sales to customers                                                $    19,650     100.0     $    17,820     100.0     10.3
Cost of products sold                                             6,902           35.1      5,486           30.8      25.8
Selling, marketing and administrative expenses                    5,396           27.5      4,772           26.8      13.1
Research and development expense                                  2,574           13.1      2,178           12.2      18.2
Interest (income) expense, net                                    155             0.8       95              0.5
Other (income) expense, net                                       (236)           (1.2)     (54)            (0.2)
Restructuring                                                     69              0.3       62              0.3
Earnings before provision for taxes on income                     4,790           24.4      5,281           29.6      (9.3)
Provision for taxes on income                                     1,026           5.2       1,009           5.6       1.7
Net earnings                                                      $      3,764    19.2      $      4,272    24.0      (11.9)
Net earnings per share (Diluted)                                  $        1.37             $        1.53             (10.5)
Average shares outstanding (Diluted)                              2,737.7                   2,785.4
Effective tax rate                                                21.4          %           19.1          %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $      6,573    33.5      $      5,831    32.7      12.7
Net earnings                                                      $      5,208    26.5      $      4,683    26.3      11.2
Net earnings per share (Diluted)                                  $        1.90             $        1.68             13.1
Effective tax rate                                                20.8          %           19.7          %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 NINE MONTHS
                                                                  2017                      2016                      Percent
                                                                                  Percent                   Percent   Increase
                                                                  Amount          to Sales  Amount          to Sales  (Decrease)
Sales to customers                                                $    56,255     100.0     $    53,784     100.0     4.6
Cost of products sold                                             18,111          32.2      16,151          30.0      12.1
Selling, marketing and administrative expenses                    15,395          27.4      14,636          27.2      5.2
Research and development expense                                  6,919           12.3      6,455           12.0      7.2
In-process research and development                               -               -         29              0.1
Interest (income) expense, net                                    360             0.6       274             0.5
Other (income) expense, net                                       192             0.3       464             0.9
Restructuring                                                     165             0.3       296             0.5
Earnings before provision for taxes on income                     15,113          26.9      15,479          28.8      (2.4)
Provision for taxes on income                                     3,100           5.5       2,753           5.1       12.6
Net earnings                                                      $    12,013     21.4      $    12,726     23.7      (5.6)
Net earnings per share (Diluted)                                  $        4.37             $        4.55             (4.0)
Average shares outstanding (Diluted)                              2,746.4                   2,796.6
Effective tax rate                                                20.5          %           17.8          %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $    18,961     33.7      $    17,656     32.8      7.4
Net earnings                                                      $    15,263     27.1      $    14,403     26.8      6.0
Net earnings per share (Diluted)                                  $        5.56             $        5.15             8.0
Effective tax rate                                                19.5          %           18.4          %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                             Third Quarter                 % Incr. /        Nine Months YTD                               % Incr. /
(Dollars in Millions Except Per Share Data)                  2017           2016           (Decr.)          2017                            2016          (Decr.)
Earnings before provision for taxes on income - as reported  $ 4,790        5,281          (9.3)         %  $ 15,113                        15,479        (2.4)                              %
Intangible asset amortization expense                        1,077          319                             1,886                           927
Litigation expense, net                                      118            55                              611                             721
Restructuring/Other (1)                                      187            109                             476                             387
Actelion acquisition related cost                            367            -                               580                             -
Diabetes asset impairment                                    (2)            -                               180                             -
AMO acquisition related cost                                 36             -                               115                             -
In-process research and development                          -              -                               -                               29
Other                                                        -              67                              -                               113
Earnings before provision for taxes on income - as adjusted  $ 6,573        5,831          12.7          %  $ 18,961                        17,656        7.4                                %
Net Earnings - as reported                                   $ 3,764        4,272          (11.9)        %  $ 12,013                        12,726        (5.6)                              %
Intangible asset amortization expense                        933            236                             1,555                           679
Litigation expense, net                                      97             46                              449                             595
Restructuring/Other                                          136            76                              358                             293
Actelion acquisition related cost                            255            -                               454                             -
Diabetes asset impairment                                    (5)            -                               120                             -
AMO acquisition related cost                                 28             -                               314                             -
In-process research and development                          -              -                               -                               23
Other                                                        -              53                              -                               87
Net Earnings - as adjusted                                   $ 5,208        4,683          11.2          %  $ 15,263                        14,403        6.0                                %
Diluted Net Earnings per share - as reported                 $   1.37       1.53           (10.5)        %  $     4.37                      4.55          (4.0)                              %
Intangible asset amortization expense                        0.34           0.08                            0.57                            0.24
Litigation expense, net                                      0.04           0.02                            0.16                            0.21
Restructuring/Other                                          0.05           0.03                            0.14                            0.11
Actelion acquisition related cost                            0.09           -                               0.16                            -
Diabetes asset impairment                                    -              -                               0.05                            -
AMO acquisition related cost                                 0.01           -                               0.11                            -
In-process research and development                          -              -                               -                               0.01
Other                                                        -              0.02                            -                               0.03
Diluted Net Earnings per share - as adjusted                 $   1.90       1.68           13.1          %  $     5.56                      5.15          8.0                                %
Operational Diluted Net Earnings per share - as adjusted at                 1.68                                                            5.19
2015 foreign currency exchange rates
Impact of currency at 2016 foreign currency exchange rates   (0.05)         -                               0.01                            (0.04)
Operational Diluted Net Earnings per share - as adjusted at  $   1.85       1.68           10.1          %  $     5.57                      5.15          8.2                                %
2016 foreign currency exchange rates
(1) Includes $29M recorded in cost of products sold and $89M recorded in other (income) expense for the third quarter 2017. Includes $46M recorded in cost of products sold
and $265M recorded in other (income) expense for nine months 2017 YTD.  Includes $3M recorded in cost of products sold and $44M recorded in other (income) expense for the
third quarter 2016.  Includes $27M recorded in cost of products sold and $64M recorded in other (income) expense for nine months 2016 YTD.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
THIRD QUARTER 2017 ACTUAL vs. 2016 ACTUAL
Segments
                                                                      Consumer  Pharmaceutical  Medical Devices  Total
                                                                      Operational %(1)
WW As Reported:                                                       1.6%      14.6%           6.6%             9.5%
U.S.                                                                  (0.5)%    15.4%           4.6%             9.7%
International                                                         3.0%      13.5%           8.6%             9.3%
Beauty
Dr. Ci: Labo                                                          (0.6)                                      (0.1)
U.S.                                                                  0.0                                        0.0
International                                                         (1.0)                                      (0.2)
Vision Care
Abbott Medical Optics                                                                           (5.2)            (1.8)
U.S.                                                                                            (4.6)            (1.5)
International                                                                                   (5.7)            (2.1)
Pulmonary Hypertension
Actelion                                                                        (7.9)                            (3.7)
U.S.                                                                            (7.7)                            (4.1)
International                                                                   (8.4)                            (3.3)
All Other Acquisitions and Divestitures                               0.1                       (0.2)            (0.1)
U.S.                                                                  (0.2)                     (0.8)            (0.3)
International                                                         0.3                       0.3              0.1
WW Ops excluding Acquisitions and Divestitures                        1.1%      6.7%            1.2%             3.8%
U.S.                                                                  (0.7)%    7.7%            (0.8)%           3.8%
International                                                         2.3%      5.1%            3.2%             3.8%
(1) Operational growth excludes the effect of translational currency
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
NINE MONTHS 2017 ACTUAL vs. 2016 ACTUAL
Segments
                                                                      Consumer  Pharmaceutical  Medical Devices  Total
                                                                      Operational %(1)
WW As Reported:                                                       1.6%      5.6%            5.3%             4.8%
U.S.                                                                  3.8%      3.8%            4.3%             4.0%
International                                                         0.2%      8.4%            6.3%             5.8%
Beauty
Vogue                                                                 (1.9)                                      (0.4)
U.S.                                                                  (4.1)                                      (0.6)
International                                                         (0.5)                                      (0.1)
Other Neuroscience
Controlled Substance Raw Material and API Business                              0.5                              0.2
U.S.                                                                            0.6                              0.3
International                                                                   0.3                              0.1
Diagnostics
Ortho-Clinical Diagnostics                                                                      0.4              0.1
U.S.                                                                                            0.0              0.0
International                                                                                   0.8              0.3
Beauty
Dr. Ci: Labo                                                          (0.3)                                      (0.1)
U.S.                                                                  0.0                                        0.0
International                                                         (0.5)                                      (0.1)
Vision Care
Abbott Medical Optics                                                                           (4.1)            (1.4)
U.S.                                                                                            (3.7)            (1.2)
International                                                                                   (4.6)            (1.7)
Pulmonary Hypertension
Actelion                                                                        (3.0)                            (1.4)
U.S.                                                                            (2.8)                            (1.5)
International                                                                   (3.3)                            (1.3)
All Other Acquisitions and Divestitures                               (0.1)                     (0.3)            0.0
U.S.                                                                  (0.4)                     (0.7)            (0.3)
International                                                         0.2                       0.2              0.0
WW Ops excluding Acquisitions and Divestitures                        (0.7)%    3.1%            1.3%             1.8%
U.S.                                                                  (0.7)%    1.6%            (0.1)%           0.7%
International                                                         (0.6)%    5.4%            2.7%             3.0%
(1) Operational growth excludes the effect of translational currency
                                    THIRD QUARTER                                                             NINE MONTHS
                                                                           % Change                                                                             % Change
                                      2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
CONSUMER SEGMENT (2) (3)
BABY CARE
US                                    $           100  $               118 -15.3%   -15.3%          -            $                  326  $                  365 -10.7%   -10.7%          -
Intl                                  377              377                 0.0%     0.0%            0.0%         1,100                   1,143                  -3.8%    -3.8%           0.0%
WW                                    477              495                 -3.6%    -3.6%           0.0%         1,426                   1,508                  -5.4%    -5.4%           0.0%
BEAUTY
US                                    523              517                 1.2%     1.2%            -            1,739                   1,555                  11.8%    11.8%           -
Intl                                  510              462                 10.4%    8.0%            2.4%         1,351                   1,279                  5.6%     5.4%            0.2%
WW                                    1,033            979                 5.5%     4.4%            1.1%         3,090                   2,834                  9.0%     8.9%            0.1%
ORAL CARE
US                                    154              156                 -1.3%    -1.3%           -            460                     485                    -5.2%    -5.2%           -
Intl                                  228              227                 0.4%     -1.4%           1.8%         678                     686                    -1.2%    -1.6%           0.4%
WW                                    382              383                 -0.3%    -1.3%           1.0%         1,138                   1,171                  -2.8%    -3.0%           0.2%
OTC
US                                    401              386                 3.9%     3.9%            -            1,310                   1,257                  4.2%     4.2%            -
Intl                                  601              557                 7.9%     4.7%            3.2%         1,711                   1,681                  1.8%     1.4%            0.4%
WW                                    1,002            943                 6.3%     4.4%            1.9%         3,021                   2,938                  2.8%     2.6%            0.2%
WOMEN’S HEALTH
US                                    3                3                   0.0%     0.0%            -            9                       16                     -43.8%   -43.8%          -
Intl                                  267              266                 0.4%     -1.9%           2.3%         779                     787                    -1.0%    -2.6%           1.6%
WW                                    270              269                 0.4%     -1.8%           2.2%         788                     803                    -1.9%    -3.5%           1.6%
WOUND CARE / OTHER
US                                    104              111                 -6.3%    -6.3%           -            342                     355                    -3.7%    -3.7%           -
Intl                                  88               81                  8.6%     5.9%            2.7%         257                     266                    -3.4%    -4.0%           0.6%
WW                                    192              192                 0.0%     -1.2%           1.2%         599                     621                    -3.5%    -3.8%           0.3%
TOTAL CONSUMER
US                                    1,285            1,291               -0.5%    -0.5%           -            4,186                   4,033                  3.8%     3.8%            -
Intl                                  2,071            1,970               5.1%     3.0%            2.1%         5,876                   5,842                  0.6%     0.2%            0.4%
WW                                    $        3,356   $            3,261  2.9%     1.6%            1.3%         $             10,062    $               9,875  1.9%     1.6%            0.3%
                                      REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    THIRD QUARTER                                                             NINE MONTHS
                                                                           % Change                                                                             % Change
                                      2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US                                    $        2,420   $            2,294  5.5%     5.5%            -            $               6,644   $               6,689  -0.7%    -0.7%           -
Intl                                  849              790                 7.5%     4.9%            2.6%         2,514                   2,343                  7.3%     7.3%            0.0%
WW                                    3,269            3,084               6.0%     5.3%            0.7%         9,158                   9,032                  1.4%     1.4%            0.0%
REMICADE
US                                    1,206            1,222               -1.3%    -1.3%           -            3,452                   3,669                  -5.9%    -5.9%           -
US Exports (4)                        156              255                 -38.8%   -38.8%          -            448                     673                    -33.4%   -33.4%          -
Intl                                  285              306                 -6.9%    -10.2%          3.3%         949                     1,000                  -5.1%    -5.9%           0.8%
WW                                    1,647            1,783               -7.6%    -8.2%           0.6%         4,849                   5,342                  -9.2%    -9.4%           0.2%
SIMPONI / SIMPONI ARIA
US                                    242              256                 -5.5%    -5.5%           -            701                     716                    -2.1%    -2.1%           -
Intl                                  234              225                 4.0%     3.2%            0.8%         642                     603                    6.5%     6.6%            -0.1%
WW                                    476              481                 -1.0%    -1.4%           0.4%         1,343                   1,319                  1.8%     1.9%            -0.1%
STELARA
US                                    800              561                 42.6%    42.6%           -            2,027                   1,631                  24.3%    24.3%           -
Intl                                  324              253                 28.1%    24.7%           3.4%         903                     722                    25.1%    26.1%           -1.0%
WW                                    1,124            814                 38.1%    37.0%           1.1%         2,930                   2,353                  24.5%    24.8%           -0.3%
OTHER IMMUNOLOGY
US                                    16               -                   *        *               -            16                      -                      *        *               -
Intl                                  6                6                   -        -               -            20                      18                     11.1%    9.4%            1.7%
WW                                    22               6                   *        *               -            36                      18                     100.0%   98.3%           1.7%
INFECTIOUS DISEASES
US                                    353              387                 -8.8%    -8.8%           -            1,020                   1,107                  -7.9%    -7.9%           -
Intl                                  460              455                 1.1%     -2.3%           3.4%         1,334                   1,340                  -0.4%    -0.4%           0.0%
WW                                    813              842                 -3.4%    -5.3%           1.9%         2,354                   2,447                  -3.8%    -3.8%           0.0%
EDURANT
US                                    15               13                  15.4%    15.4%           -            44                      38                     15.8%    15.8%           -
Intl                                  179              136                 31.6%    26.0%           5.6%         478                     370                    29.2%    28.9%           0.3%
WW                                    194              149                 30.2%    25.1%           5.1%         522                     408                    27.9%    27.7%           0.2%
PREZISTA / PREZCOBIX / REZOLSTA
US                                    287              310                 -7.4%    -7.4%           -            824                     860                    -4.2%    -4.2%           -
Intl                                  180              183                 -1.6%    -5.5%           3.9%         527                     544                    -3.1%    -2.7%           -0.4%
WW                                    467              493                 -5.3%    -6.7%           1.4%         1,351                   1,404                  -3.8%    -3.7%           -0.1%
OTHER INFECTIOUS DISEASES
US                                    51               64                  -20.3%   -20.3%          -            152                     209                    -27.3%   -27.3%          -
Intl                                  101              136                 -25.7%   -26.4%          0.7%         329                     426                    -22.8%   -23.1%          0.3%
WW                                    152              200                 -24.0%   -24.5%          0.5%         481                     635                    -24.3%   -24.5%          0.2%
See footnotes at end of schedule
                                      REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    THIRD QUARTER                                                             NINE MONTHS
                                                                           % Change                                                                             % Change
                                      2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
NEUROSCIENCE
US                                    647              622                 4.0%     4.0%            -            1,931                   1,997                  -3.3%    -3.3%           -
Intl                                  851              842                 1.1%     0.6%            0.5%         2,531                   2,618                  -3.3%    -2.2%           -1.1%
WW                                    1,498            1,464               2.3%     2.0%            0.3%         4,462                   4,615                  -3.3%    -2.7%           -0.6%
CONCERTA / METHYLPHENIDATE
US                                    100              102                 -2.0%    -2.0%           -            284                     365                    -22.2%   -22.2%          -
Intl                                  98               88                  11.4%    10.5%           0.9%         304                     294                    3.4%     4.1%            -0.7%
WW                                    198              190                 4.2%     3.8%            0.4%         588                     659                    -10.8%   -10.5%          -0.3%
INVEGA SUSTENNA / XEPLION / TRINZA
US                                    395              339                 16.5%    16.5%           -            1,154                   983                    17.4%    17.4%           -
Intl                                  248              217                 14.3%    11.0%           3.3%         722                     646                    11.8%    12.8%           -1.0%
WW                                    643              556                 15.6%    14.3%           1.3%         1,876                   1,629                  15.2%    15.6%           -0.4%
RISPERDAL CONSTA
US                                    87               94                  -7.4%    -7.4%           -            273                     289                    -5.5%    -5.5%           -
Intl                                  107              128                 -16.4%   -18.0%          1.6%         335                     394                    -15.0%   -14.0%          -1.0%
WW                                    194              222                 -12.6%   -13.5%          0.9%         608                     683                    -11.0%   -10.4%          -0.6%
OTHER NEUROSCIENCE
US                                    65               87                  -25.3%   -25.3%          -            220                     360                    -38.9%   -38.9%          -
Intl                                  398              409                 -2.7%    -1.4%           -1.3%        1,170                   1,284                  -8.9%    -7.7%           -1.2%
WW                                    463              496                 -6.7%    -5.6%           -1.1%        1,390                   1,644                  -15.5%   -14.5%          -1.0%
ONCOLOGY
US                                    846              622                 36.0%    36.0%           -            2,207                   1,740                  26.8%    26.8%           -
Intl                                  1,052            895                 17.5%    15.2%           2.3%         3,012                   2,605                  15.6%    16.8%           -1.2%
WW                                    1,898            1,517               25.1%    23.8%           1.3%         5,219                   4,345                  20.1%    20.8%           -0.7%
DARZALEX
US                                    230              124                 85.5%    85.5%           -            643                     320                    *        *               -
Intl                                  87               39                  *        *               *            228                     52                     *        *               *
WW                                    317              163                 94.5%    92.0%           2.5%         871                     372                    *        *               *
IMBRUVICA
US                                    230              179                 28.5%    28.5%           -            622                     455                    36.7%    36.7%           -
Intl                                  282              170                 65.9%    61.8%           4.1%         749                     450                    66.4%    67.7%           -1.3%
WW                                    512              349                 46.7%    44.7%           2.0%         1,371                   905                    51.5%    52.1%           -0.6%
VELCADE
US                                    -                -                   -        -               -            -                       -                      -        -               -
Intl                                  273              304                 -10.2%   -11.2%          1.0%         843                     950                    -11.3%   -9.8%           -1.5%
WW                                    273              304                 -10.2%   -11.2%          1.0%         843                     950                    -11.3%   -9.8%           -1.5%
ZYTIGA
US                                    352              282                 24.8%    24.8%           -            826                     840                    -1.7%    -1.7%           -
Intl                                  317              300                 5.7%     4.4%            1.3%         924                     901                    2.6%     3.5%            -0.9%
WW                                    669              582                 14.9%    14.2%           0.7%         1,750                   1,741                  0.5%     1.0%            -0.5%
OTHER ONCOLOGY
US                                    34               37                  -8.1%    -8.1%           -            116                     125                    -7.2%    -7.2%           -
Intl                                  93               82                  13.4%    11.1%           2.3%         268                     252                    6.3%     7.3%            -1.0%
WW                                    127              119                 6.7%     5.1%            1.6%         384                     377                    1.9%     2.6%            -0.7%
PULMONARY HYPERTENSION(5)
US                                    387              -                   *        *               -            427                     -                      *        *               -
Intl                                  283              -                   *        *               -            334                     -                      *        *               -
WW                                    670              -                   *        *               -            761                     -                      *        *               -
OPSUMIT                                                -
US                                    150              -                   *        *               -            174                     -                      *        *               -
Intl                                  109              -                   *        *               -            130                     -                      *        *               -
WW                                    259              -                   *        *               -            304                     -                      *        *               -
TRACLEER                                               -
US                                    83               -                   *        *               -            85                      -                      *        *               -
Intl                                  127              -                   *        *               -            151                     -                      *        *               -
WW                                    210              -                   *        *               -            236                     -                      *        *               -
UPTRAVI                                                -
US                                    113              -                   *        *               -            121                     -                      *        *               -
Intl                                  11               -                   *        *               -            12                      -                      *        *               -
WW                                    124              -                   *        *               -            133                     -                      *        *               -
OTHER                                                  -
US                                    41               -                   *        *               -            47                      -                      *        *               -
Intl                                  36               -                   *        *               -            41                      -                      *        *               -
WW                                    77               -                   *        *               -            88                      -                      *        *               -
CARDIOVASCULAR / METABOLISM / OTHER
US                                                     1,163               1,117               4.1%     4.1%            -            3,469                   3,590                  -3.4%    -3.4%           -
Intl                                                   384                 376                 2.1%     1.0%            1.1%         1,152                   1,203                  -4.2%    -2.2%           -2.0%
WW                                                     1,547               1,493               3.6%     3.3%            0.3%         4,621                   4,793                  -3.6%    -3.1%           -0.5%
XARELTO
US                                                     635                 529                 20.0%    20.0%           -            1,790                   1,690                  5.9%     5.9%            -
Intl                                                   -                   -                   -        -               -            -                       -                      -        -               -
WW                                                     635                 529                 20.0%    20.0%           -            1,790                   1,690                  5.9%     5.9%            -
INVOKANA / INVOKAMET
US                                                     220                 294                 -25.2%   -25.2%          -            723                     939                    -23.0%   -23.0%          -
Intl                                                   45                  34                  32.4%    31.6%           0.8%         121                     97                     24.7%    26.5%           -1.8%
WW                                                     265                 328                 -19.2%   -19.3%          0.1%         844                     1,036                  -18.5%   -18.3%          -0.2%
PROCRIT / EPREX
US                                                     168                 168                 0.0%     0.0%            -            511                     581                    -12.0%   -12.0%          -
Intl                                                   70                  82                  -14.6%   -17.6%          3.0%         229                     265                    -13.6%   -13.3%          -0.3%
WW                                                     238                 250                 -4.8%    -5.8%           1.0%         740                     846                    -12.5%   -12.4%          -0.1%
OTHER
US                                                     140                 126                 11.1%    11.1%           -            445                     380                    17.1%    17.1%           -
Intl                                                   269                 260                 3.5%     2.9%            0.6%         802                     841                    -4.6%    -2.1%           -2.5%
WW                                                     409                 386                 6.0%     5.6%            0.4%         1,247                   1,221                  2.1%     3.8%            -1.7%
TOTAL PHARMACEUTICAL
US                                                     5,816               5,042               15.4%    15.4%           -            15,698                  15,123                 3.8%     3.8%            -
Intl                                                   3,879               3,358               15.5%    13.5%           2.0%         10,877                  10,109                 7.6%     8.4%            -0.8%
WW                                                     $        9,695      8,400               15.4%    14.6%           0.8%         $             26,575    25,232                 5.3%     5.6%            -0.3%
See footnotes at end of schedule
                                                       REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    THIRD QUARTER                                                                                 NINE MONTHS
                                                                                               % Change                                                                             % Change
MEDICAL DEVICES SEGMENT (2)                            2017                2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
CARDIOVASCULAR
US                                                     $           261     235                 11.1%    11.1%           -            $                  785  701                    12.0%    12.0%           -
Intl                                                   245                 216                 13.4%    13.9%           -0.5%        743                     663                    12.1%    13.5%           -1.4%
WW                                                     506                 451                 12.2%    12.5%           -0.3%        1,528                   1,364                  12.0%    12.7%           -0.7%
DIABETES CARE
US                                                     168                 191                 -12.0%   -12.0%          -            482                     548                    -12.0%   -12.0%          -
Intl                                                   237                 236                 0.4%     -2.6%           3.0%         743                     779                    -4.6%    -4.6%           0.0%
WW                                                     405                 427                 -5.2%    -6.9%           1.7%         1,225                   1,327                  -7.7%    -7.7%           0.0%
DIAGNOSTICS
US                                                     -                   -                   -        -               -            -                       -                      -        -               -
Intl                                                   -                   7                   *        *               *            1                       66                     *        *               *
WW                                                     -                   7                   *        *               *            1                       66                     *        *               *
ORTHOPAEDICS
US                                                     1,326               1,343               -1.3%    -1.3%           -            4,092                   4,099                  -0.2%    -0.2%           -
Intl                                                   925                 908                 1.9%     0.0%            1.9%         2,827                   2,848                  -0.7%    -0.2%           -0.5%
WW                                                     2,251               2,251               0.0%     -0.8%           0.8%         6,919                   6,947                  -0.4%    -0.2%           -0.2%
HIPS
US                                                     195                 190                 2.6%     2.6%            -            612                     590                    3.7%     3.7%            -
Intl                                                   133                 130                 2.3%     -0.1%           2.4%         418                     421                    -0.7%    -0.1%           -0.6%
WW                                                     328                 320                 2.5%     1.5%            1.0%         1,030                   1,011                  1.9%     2.2%            -0.3%
KNEES
US                                                     220                 223                 -1.3%    -1.3%           -            702                     696                    0.9%     0.9%            -
Intl                                                   123                 132                 -6.8%    -9.5%           2.7%         424                     433                    -2.1%    -1.4%           -0.7%
WW                                                     343                 355                 -3.4%    -4.4%           1.0%         1,126                   1,129                  -0.3%    0.0%            -0.3%
TRAUMA
US                                                     398                 389                 2.3%     2.3%            -            1,179                   1,151                  2.4%     2.4%            -
Intl                                                   264                 248                 6.5%     4.6%            1.9%         768                     764                    0.5%     0.8%            -0.3%
WW                                                     662                 637                 3.9%     3.1%            0.8%         1,947                   1,915                  1.7%     1.8%            -0.1%
SPINE & OTHER
US                                                     513                 541                 -5.2%    -5.2%           -            1,599                   1,662                  -3.8%    -3.8%           -
Intl                                                   405                 398                 1.8%     0.3%            1.5%         1,217                   1,230                  -1.1%    -0.5%           -0.6%
WW                                                     918                 939                 -2.2%    -2.8%           0.6%         2,816                   2,892                  -2.6%    -2.3%           -0.3%
SURGERY
US                                                     1,002               1,002               0.0%     0.0%            -            3,009                   3,003                  0.2%     0.2%            -
Intl                                                   1,344               1,282               4.8%     3.7%            1.1%         3,992                   3,906                  2.2%     2.9%            -0.7%
WW                                                     2,346               2,284               2.7%     2.1%            0.6%         7,001                   6,909                  1.3%     1.7%            -0.4%
ADVANCED
US                                                     398                 390                 2.1%     2.1%            -            1,190                   1,131                  5.2%     5.2%            -
Intl                                                   525                 494                 6.3%     5.3%            1.0%         1,543                   1,478                  4.4%     5.4%            -1.0%
WW                                                     923                 884                 4.4%     3.9%            0.5%         2,733                   2,609                  4.8%     5.3%            -0.5%
GENERAL
US                                                     430                 414                 3.9%     3.9%            -            1,276                   1,254                  1.8%     1.8%            -
Intl                                                   675                 649                 4.0%     2.8%            1.2%         2,017                   2,006                  0.5%     1.1%            -0.6%
WW                                                     1,105               1,063               4.0%     3.2%            0.8%         3,293                   3,260                  1.0%     1.4%            -0.4%
SPECIALTY
US                                                     174                 198                 -12.1%   -12.1%          -            543                     618                    -12.1%   -12.1%          -
Intl                                                   144                 139                 3.6%     2.8%            0.8%         432                     422                    2.4%     2.1%            0.3%
WW                                                     318                 337                 -5.6%    -5.9%           0.3%         975                     1,040                  -6.3%    -6.4%           0.1%
VISION CARE
US                                                     432                 277                 56.0%    56.0%           -            1,142                   767                    48.9%    48.9%           -
Intl                                                   659                 462                 42.6%    43.9%           -1.3%        1,802                   1,297                  38.9%    39.8%           -0.9%
WW                                                     1,091               739                 47.6%    48.4%           -0.8%        2,944                   2,064                  42.6%    43.2%           -0.6%
CONTACT LENSES / OTHER
US                                                     302                 277                 9.0%     9.0%            -            832                     767                    8.5%     8.5%            -
Intl                                                   498                 462                 7.8%     9.1%            -1.3%        1,404                   1,297                  8.2%     9.1%            -0.9%
WW                                                     800                 739                 8.3%     9.1%            -0.8%        2,236                   2,064                  8.3%     8.9%            -0.6%
SURGICAL
US                                                     130                 -                   *        *               -            310                     -                      *        *               -
Intl                                                   161                 -                   *        *               -            398                     -                      *        *               -
WW                                                     291                 -                   *        *               -            708                     -                      *        *               -
TOTAL MEDICAL DEVICES
US                                                     3,189               3,048               4.6%     4.6%            -            9,510                   9,118                  4.3%     4.3%            -
Intl                                                   3,410               3,111               9.6%     8.6%            1.0%         10,108                  9,559                  5.7%     6.3%            -0.6%
WW                                                     $        6,599      6,159               7.1%     6.6%            0.5%         $             19,618    18,677                 5.0%     5.3%            -0.3%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
(5) Actelion acquisition completed June 16, 2017

https://mma.prnewswire.com/media/584657/jnj_logo_rgb.jpg

View original content with multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2017-third-quarter-results-30053777

SOURCE Johnson & Johnson

https://rt.prnewswire.com/rt.gif?NewsItemId=NY17383&Transmission_Id=201710170640PR_NEWS_USPR_____NY17383&DateId=20171017



Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.